Rab3a, a small GTP-binding protein, is required for the stabilization of the murine leukaemia virus Gag protein

Small GTPases. 2022 Jan;13(1):162-182. doi: 10.1080/21541248.2021.1939631. Epub 2021 Jun 27.

Abstract

We recently identified a CD63-interacting protein to understand the role of CD63 in virion production of the human immunodeficiency virus type 1, and we have found that Rab3a forms a complex with CD63. In this study, we analysed the effect of Rab3a on virion production of the murine leukaemia virus (MLV), which is another member of the retrovirus family. We found that Rab3a silencing induced lysosomal degradation of the MLV Gag protein, and recovery of the Rab3a expression restored the level of the Gag protein through a complex formation of MLV Gag and Rab3a, indicating that Rab3a is required for MLV Gag protein expression. In contrast, CD63 silencing decreased the infectivity of released virions but had no effect on virion production, indicating that CD63 facilitates the infectivity of released MLV particles. Although Rab3a induced CD63 degradation in uninfected cells, the complex of MLV Gag and Rab3a suppressed the Rab3a-mediated CD63 degradation in MLV-infected cells. Finally, we found that the MLV Gag protein interacts with Rab3a to stabilize its own protein and CD63 that facilitates the infectivity of released MLV particles. Considering the involvement of Rab3a in lysosome trafficking to the plasma membrane, it may also induce cell surface transport of the MLV Gag protein.

Keywords: CD63; Murine leukaemia virus; Rab3a; gag protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Membrane / metabolism
  • GTP-Binding Proteins / metabolism
  • Gene Products, gag* / metabolism
  • Humans
  • Leukemia Virus, Murine* / metabolism
  • Mice
  • Virion / metabolism

Substances

  • Gene Products, gag
  • GTP-Binding Proteins

Grants and funding

The Japan Society for the Promotion of Sciences (15K08499), the Research Program on HIV/AIDS from the Japan Agency for Medical Research and Development (AMED) (JP17fk0410204), and the Asahi Kasei Medical Co., Ltd funded this study;Japan Agency for Medical Research and Development [JP17fk0410204];Japan Society for the Promotion of Science [15K08499];Asahikasei Medical Co LTD;